BIONTECH SE SPON. ADRS 1
Commented by Fabian Lorenz on August 31st, 2021 | 10:37 CEST
Sales explosion? Novavax and Diamcor on the trail of BioNTech
When companies suddenly report strong jumps in sales, investors should take a closer look. On the one hand, there may be considerable opportunities for share price gains. On the other hand, it must also be checked whether the development is sustainable or whether it is a one-off or seasonal event. BioNTech has impressively shown that the Company and the share can profit from a sudden increase in sales. Who is next? Investors should take a closer look at the vaccine developer Novavax and the diamond producer Diamcor - it could be worthwhile.
Read
Commented by Stefan Feulner on August 27th, 2021 | 11:53 CEST
BioNTech, XPhyto, Moderna - Boosters for the portfolio
Globally, infection numbers are rising dramatically due to the highly contagious Delta variant. According to the RKI, 12,626 new infections were reported in Germany alone, 4,226 more than a week ago. With the incidence rising above the authoritative level of 35, greater emphasis is again being placed on the rule, vaccinated, recovered or tested. As a result, demand for PCR or rapid tests is skyrocketing. Diagnostic companies, like vaccine producers, are in for a warm cash shower.
Read
Commented by Nico Popp on August 26th, 2021 | 10:41 CEST
BioNTech, Cardiol Therapeutics, Bayer: Where Covid-19 still provides returns
The pandemic has not only brought losers. There is also a long list of winners. Starting with Amazon and Deutsche Post and ending with BioNTech. Before Corona, the latter Company was always considered a beacon of hope around mRNA technology. Then came the pandemic, and suddenly several small test balloons turned into a gigantic project as we know it today, with a successful outcome. We shed light on BioNTech and also focus on other potential winners of the pandemic.
Read
Commented by Stefan Feulner on August 25th, 2021 | 13:25 CEST
BioNTech, Kainantu Resources, QIAGEN - A threatening development
Most recently, with the appearance of the highly infectious Delta variant, it is clear that the Corona pandemic is not over. Infection numbers are rising, and the fourth wave has reached Germany. To better prepare for the growing number of cases this fall and avoid another hard lockdown, policymakers are relying on greater use of Corona testing in addition to vaccination programs. The higher demand for testing, also considering the start of the new school year, is again making the coffers of diagnostics companies ring.
Read
Commented by Fabian Lorenz on August 24th, 2021 | 11:27 CEST
BioNTech, Standard Lithium, Desert Gold - Before the breakout?
Following record highs, the stock markets consolidated last week. The same was true for high-flyer stocks BioNTech and Standard Lithium. Although investors continue to fear persistently high inflation, both companies can benefit from positive news and have started the new stock market week on a positive note. Thus, the lethargy is over and the old record highs are being targeted. Those who want to hedge against inflation fears should look at Desert Gold as a speculative alternative. The consolidation could soon be over for the gold explorer as well.
Read
Commented by André Will-Laudien on August 23rd, 2021 | 12:25 CEST
BioNTech, Defence Therapeutics, Dermapharm, NanoRepro - Vaccinate, Test, Treat!
The vaccination rate in Germany is now just under 59% with complete second vaccination. The Ministry of Health had assumed a 70-80% rate by late summer. The situation has now changed, and the autumn in Germany will likely take place under different conditions. Since the beginning of August, the many travelers returning home have had to undergo a test at the entry border to Germany. Presumably, the number of infections will also rise again, making testing mandatory for social life. Vaccination and testing, therefore, remain ongoing issues for the capital markets.
Read
Commented by Armin Schulz on August 16th, 2021 | 13:27 CEST
BioNTech, XPhyto Therapeutics, Siemens Healthineers - Corona has triggered a boom
While many companies have suffered greatly from the Corona pandemic, there are also a number of winners. First and foremost, vaccine manufacturers but also diagnostics companies experienced substantial growth rates in sales. Irrespective of Corona, it is increasingly crucial for the healthcare sector to push ahead with digitization, especially in diagnostics. Here, digitization offers the opportunity to significantly increase the quality and speed of diagnoses through artificial intelligence. Time, in particular, is an important factor here. Today, we take a closer look at three beneficiaries of the Corona Crisis.
Read
Commented by Fabian Lorenz on August 10th, 2021 | 11:57 CEST
Hot autumn for BioNTech, NanoRepro and XPhyto: Nothing works without testing and vaccination
Shares of Corona vaccine and test manufacturers are in for a hot fall. Summer is drawing to a close, and the Delta variant is hard to stop. Calls for stricter measures are growing. Politicians are calling for vaccination premiums and mandatory testing for travelers returning home. The 1st FC Cologne recently announced that it would only allow vaccinated people into the stadium. BioNTech, NanoRepro and XPhyto are among the beneficiaries of this development. The latter Company could also benefit from demands from politicians. SPD health expert Karl Lauterbach called for mandatory "PCR" testing for unvaccinated people before visiting restaurants.
Read
Commented by André Will-Laudien on August 6th, 2021 | 11:07 CEST
BioNTech, Formycon, Aztec Minerals, NanoRepro - Rollercoaster rides in the summer lull!
Summer lull and total standstill! Who has not just invested in BioNTech or Northern Data feels barely any movement in the portfolio. The stock exchanges are rehearsing the standstill, somehow nothing is going up, but this does not mean that things have to fall. Old sayings such as "What goes up, must come down!" have already been outdated for some time. For some stocks, the fantasy lasts endlessly; for other former hype candidates, the rally ends in the shredder. The hydrogen stock Nel has now lost 20% in one week. Many will say no problem because the stock market darling stands on a 3-year view still over 300% in the plus. Just someone probably has his initial investment above EUR 3. We keep trying with selective ideas.
Read
Commented by André Will-Laudien on August 4th, 2021 | 11:23 CEST
MorphoSys, Defence Therapeutics, BioNTech, Pfizer - The next biotech explosion!
Infectious diseases are diseases transmitted by pathogens such as bacteria, viruses or fungi. Depending on which organs and body parts they affect, they can cause very different symptoms. In Covid-19, we are dealing with a problematic initial situation because not every infected person has apparent symptoms at all. Moreover, the virus can also be transmitted from vaccinated individuals to the next host without any problems. That shows the high relevance of testing, despite increasing vaccination rates. On the one hand, the biotech sector is concerned with diagnostic procedures and, on the other hand, with suitable vaccinations to best prepare our immune system for the fight. In the current pandemic, the coming winter will also indicate the overall effectiveness of vaccines.
Read